MILAN (EGMN) - Hope for patients with melanoma who develop brain metastases may be on the horizon with the finding that a novel targeted agent reduces the size of multiple brain lesions.Data from a phase I/II study in 10 patients show that all but one of the participants treated with the oral agent GSK2118436 experienced a partial or complete response, with overall reductions in the size of brain metastases ranging...